Company profile: Celleron Therapeutics
1.1 - Company Overview
Company description
- Provider of oncology therapeutics and biomarker-driven precision medicine, developing epigenetic biomarkers to match drugs to responsive disease. Pipeline includes Zabadinostat, an immune modulator with clinical activity in colorectal cancer, liver cancer, and lymphoma; PCV-001, a preclinical precision cancer vaccine; and AT-101, an in-house PRMT5 inhibitor in clinical planning.
Products and services
- Zabadinostat: A clinical-stage immune modulator that improves antigen presentation and natural killer cell activity, demonstrating clinical activity in colorectal cancer, liver cancer, and lymphoma
- AT-101: A small-molecule PRMT5 inhibitor, developed in-house and in clinical planning, to explore treating cancers with PRMT5-driven tumor response
- PCV-001: A preclinical-stage precision cancer vaccine that trains the immune system to recognize novel tumor-associated antigens on immunologically cold tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Celleron Therapeutics
PT Theragnostic
HQ: The Netherlands
Website
- Description: Provider of genomics-based personalized analysis for radiation sensitivity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PT Theragnostic company profile →
Zentalis
HQ: United States
Website
- Description: Provider of small molecule oncology therapeutics and discovery capabilities, including Azenosertib, a Wee1 inhibitor for advanced solid tumors; ZN-d5, an oral BCL-2 inhibitor for hematologic malignancies; a heterobifunctional degrader of BCL-xL for solid and hematologic cancers; and an Integrated Discovery Engine for identifying novel therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zentalis company profile →
Amcure
HQ: Germany
Website
- Description: Provider of peptide-based compounds in clinical development for the treatment of highly metastatic forms of squamous cancer; a privately held spin-off from the Karlsruhe Institute of Technology established in 2012 and supported by a grant from the German Federal Ministry of Education and Research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amcure company profile →
GamaMabs
HQ: France
Website
- Description: Provider of optimized monoclonal antibody therapeutics for cancer, developing clinical-stage immuno-oncology candidates including GM102 (formerly 3C23K), a mAb targeting the anti-Müllerian hormone receptor (AMHR2) in gynecological cancers, currently in phase Ia/Ib.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GamaMabs company profile →
Eikonoklastes
HQ: United States
Website
- Description: Provider of gene therapies that increase Caveolin-1 expression in neurons to address neurodegenerative diseases, including ET-101, designed to overexpress Caveolin-1 and potentially benefit patients with ALS, Parkinson’s, Huntington’s, MS, and dementia, and SynCav1, which enhances neuroprotection and neuroplasticity for a wide range of neurodegenerative conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eikonoklastes company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Celleron Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Celleron Therapeutics
2.2 - Growth funds investing in similar companies to Celleron Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Celleron Therapeutics
4.2 - Public trading comparable groups for Celleron Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →